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Abstract
Cryptococcus gattii is an encapsulated fungus capable of causing fatal disease in immunocompetent humans and animals.
As current antifungal therapies are few and limited in efficacy, and resistance is an emerging issue, the development of new
treatment strategies is urgently required. The current study undertook a time-course analysis of the proteome of C. gattii
during treatment with fluconazole (FLC), which is used widely in prophylactic and maintenance therapies. The aims were to
analyze the overall cellular response to FLC, and to find fungal proteins involved in this response that might be useful
targets in therapies that augment the antifungal activity of FLC. During FLC treatment, an increase in stress response, ATP
synthesis and mitochondrial respiratory chain proteins, and a decrease in most ribosomal proteins was observed,
suggesting that ATP-dependent efflux pumps had been initiated for survival and that the maintenance of ribosome
synthesis was differentially expressed. Two proteins involved in fungal specific pathways were responsive to FLC. An
integrative network analysis revealed co-ordinated processes involved in drug response, and highlighted hubs in the
network representing essential proteins that are required for cell viability. This work demonstrates the dynamic cellular
response of a typical susceptible isolate of C. gattii to FLC, and identified a number of proteins and pathways that could be
targeted to augment the activity of FLC.
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Introduction
Fungal diseases are an emerging problem worldwide. Globally,
immunosuppression due to HIV/AIDS is the most important risk
factor for developing systemic fungal infections. In the developed
world, medical advances such as organ transplants and chemo-
therapy, along with increases in diabetes, obesity and old age,
cause vulnerability to a wide spectrum of fungal infections.
Ongoing changes in fungal ecology and range expansion have also
been implicated in some recent outbreaks of previously uncom-
mon mycoses [1,2,3].
Aggressive antifungal treatment is frequently required to resolve
serious mycoses, especially in debilitated hosts. Unfortunately, the
available antifungal therapies are very limited in scope and
spectrum. Current antifungal drugs work via only five different
mechanisms, and of these only three classes of drugs can be used to
treat systemic infections effectively [4]. The polyene class includes
amphotericin B, which is fungicidal and highly effective against
most fungal pathogens but also toxic to mammalian cells and is
associated with serious side effects. Azole-based drugs, which
include fluconazole and newer triazoles, are generally well
tolerated but cannot be used during pregnancy, are ineffective
against some important pathogens including Fusarium, Scedosporium
and the zygomycetes, and can induce resistance. Echinocandins
are the newest class of antifungal drug and are highly effective
against Candida and Aspergillus species but show no activity against
Cryptococcus, Fusarium and the zygomycetes, and resistance is an
emerging issue [5].
The development of new antifungals is difficult as targeted
structures or cellular pathways must be sufficiently conserved
among the fungi to ensure broad-spectrum coverage (and hence a
profitable market for pharmaceutical companies), but sufficiently
divergent between fungi and animals to prevent cross-reactivity
and undesirable side effects. A promising alternative approach to
the de novo development of new drugs is to develop therapies that
work in synergy with existing drugs, either by targeting cellular
pathways that enhance drug action or block the development of
resistance, or by augmenting the host response, thereby speeding
up clearance of the pathogen.
Cryptococcosis is one of the most important systemic mycoses,
and Cryptococcus has become an important model organism for
studies of fungal virulence and host response. Cryptococcus neofor-
mans, a major AIDS-related pathogen, causes over one million
infections and more than 650,000 deaths per year, rivaling
tuberculosis in importance in many parts of the world [6]. The
related species C. gattii, although rarely found in the immuno-
compromised, is an important primary pathogen and is respon-
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sible for a significant ongoing outbreak in otherwise healthy people
and animals in the Pacific Northwest of Canada and the United
States [1]. Most Cryptococcus strains are susceptible to FLC, which is
widely used in prophylactic and maintenance therapy. However,
some C. gattii isolates have reduced FLC susceptibility, despite
having never been exposed to azole-based drugs. This appears to
segregate with genotype, such that genotype VGII is significantly
less susceptible than genotypes VGI and VGIII [7,8]. The reason
for these different responses is not known.
Understanding how a pathogen responds to a drug is today best
achieved using systems biology approaches that enable the entire
cellular response to be investigated. Proteomics, where expressed
proteins are identified and quantified, has been employed to
investigate the response of Candida albicans and Candida glabrata to
antifungals such as azoles and polyenes [9,10]. Few proteomic
studies have been conducted on Cryptococcus, and none have
investigated its response to antifungals. The ability to profile the
global response to an antifungal agent makes it possible to identify
proteins that are not directly affected by the antifungal drug but
are modulated in response to the stress that the drug imposes.
Since these may be important for allowing the fungal cell to
survive they are potential targets for use in synergistic therapies. In
this study, we analyzed the proteome of a representative,
moderately susceptible strain of C. gattii VGII during growth in
the presence and absence of FLC. The aims of this work were 1) to
determine a baseline proteome for C. gattii during normal early to
mid log growth; 2) to characterize proteins that are differentially
expressed during FLC treatment; and 3) to use network analysis to
identify key cellular products or pathways that might form suitable
targets for synergistic therapies with FLC. Cellular proteins
involved in stress response, macromolecule biosynthesis and
energy production for growth were affected during growth and
in response to FLC, and the changes in expression of these
proteins over time were dynamic and multiple. Network analysis of
these differentially expressed proteins revealed co-ordinated
processes involved in the drug response that may be suitable
targets for synergistic therapies with FLC.
Results
Cell size and protein yield increase with FLC treatment
Growth of a representative, moderately susceptible C. gattii
isolate was initially assessed in the presence of 20 and 100 mg/mL
FLC. Growth of all cell cultures was affected after exposure to
FLC for 2 hours (Figure 1), and cell imaging revealed changes to
cellular morphology during FLC treatment (Figure 2). There were
no significant differences in capsule size among cells treated with
or without FLC at each time point (p$0.65). However, cells
treated with either concentration of FLC for 4 h and 6 h were
significantly larger than the untreated cells (p,0.001) and the cells
treated with FLC for 3 h (p#0.004). Cells treated with 20 mg/mL
of FLC had a similar size to cells treated with 100 mg/mL of FLC
at three different time points (p$0.25). There was no difference in
the size of cells treated with FLC for 4 h and 6 h (p$0.15), or
between untreated cells and those treated with FLC for 3 h
(p$0.07).
Total protein in samples was quantified to assess the yield of
protein per C. gattii cell volume. Protein yield from the untreated
cells was similar across the three different time points
(,3.661027 mg/mm3; p$0.074). In contrast, the yield from the
samples treated with FLC dropped significantly from
,3.961027 mg/mm3 at 3 hours to ,2.661027 mg/mm3 and
,3.161027 mg/mm3, for 4 and 6 h respectively (p#0.03). These
were also lower than the respective untreated samples at 4 and 6 h
(p,0.012) but higher than the untreated samples at 3 h (p=0.027).
Numerous cellular responses occur during growth in the
presence or absence of FLC
Changes in protein expression were analysed to assess
differential protein expression patterns during growth of C. gattii
in the absence or presence of FLC (Table S1). The differentially
regulated proteins were grouped into ten functional groups: stress
response, signal transduction, ribosomal proteins, sugar or lipid
metabolism, protein or amino acid metabolism, plasma membrane
proteins, nuclear proteins, cytoskeleton proteins, miscellaneous
proteins and uncharacterized proteins with unknown functions.
In the untreated samples, a total of 195 proteins were identified,
while 152 proteins were identified across all of the FLC-treated
samples. When all of the proteins identified were compared, 12
were found only in the FLC-treated samples. The majority of
proteins found only in the untreated samples had functions
involving protein or amino acid metabolism, ribosomal biosyn-
thesis or energy metabolism including respiration and glycolysis. In
contrast, most of the proteins found only in the FLC-treated
samples were uncharacterized proteins without known functions,
or were involved in protein and sugar metabolism (Figure 3; Table
S1).
Protein expression profiles of the untreated and FLC-treated
samples at the middle (4 h) and late (6 h) stages of drug response
were compared to those at the early (3 h) stage of the drug
response to examine how protein expression patterns changed
over time (Table S1). During normal (drug-free) growth, 99
proteins were induced (ie. only found in middle-late stage) or
differentially expressed. Of these, 41 proteins were present only in
the 6-hour sample, with the majority having a role in protein or
amino acid metabolism or energy production (respiration,
glycolysis and tricarboxylic acid cycle), and the remainder involved
in the stress response and in the biosynthesis of ribosomes, the
plasma membrane and the cytoskeleton. These results are
consistent with normal early exponential phase growth, as the
nutrients were sufficient for cells to multiply without any major
stress, and in doing so the cells produced more proteins. During
growth in the presence of FLC, 56 proteins were induced or
differentially regulated in mid-late growth (Table S1), with 30 of
these found exclusively in the 6-h FLC-treated samples. Compared
to the change in expression patterns observed during normal
growth, there were reduced numbers of various proteins involved
in energy production and protein synthesis, particularly ribosomal
proteins, consistent with the slowing of active metabolism and
growth.
Dynamic overview of the antifungal response to FLC over
time
To investigate the metabolic pathways affected by FLC, protein
expression profiles were compared between the FLC-treated and
the untreated cells at each of the three time points (Table S2). In
the response to FLC over time, reduced levels of ribosomal
proteins and increasing levels of heat shock proteins, plasma
membrane proteins, and various proteins involved in sugar
metabolism, ATP synthesis and the mitochondrial respiratory
chain were observed. Five proteins were consistently up-regulated
or induced by FLC, and these included 14-3-3 protein, 40S
ribosomal protein S7, 60S ribosomal protein L6, cytochrome c
oxidase subunit 2 and peripheral-type benzodiazepine receptor.
Two proteins involved in fungal-specific pathways were differen-
tially expressed in response to FLC. Of these, G protein beta
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subunit Gib2 was down-regulated at each time point, while
isoprenoid biosynthesis-related protein was up-regulated at
6 hours.
Co-ordinated processes involved in drug response
revealed by network analysis
As the proteome analysis revealed dynamic changes in protein
expression in cells treated with FLC over time, network analysis
was used to gain further insight into how the differentially
regulated proteins might interact with each other, and how the
cells co-ordinate their response to FLC over time. High-quality
protein-protein interaction data for the yeast Saccharomyces cerevisiae
were used to generate the networks, as protein-protein interactions
Figure 1. The effect of FLC on growth of C. gattii VGII in YPDmedia. A susceptible strain V5 was tested in the presence of FLC at two different
concentrations. Growth of V5 was inhibited after 2 h of drug exposure. Data are shown as mean +/2 standard error.
doi:10.1371/journal.pone.0042835.g001
Figure 2. The effect of FLC treatment on the morphology of C.
gattii cells. Data are shown as mean +/2 standard error. * indicates
P,0.05 and ** indicates P,0.001.
doi:10.1371/journal.pone.0042835.g002
Figure 3. Categories of proteins that were present only in the
FLC-treated or in the untreated samples. Proteins involved in
energy production, protein metabolism and ribosomal protein synthe-
sis were substantially reduced in the FLC-treated cells, while the
number of unknown proteins increased in the FLC-treated cells.
doi:10.1371/journal.pone.0042835.g003
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have not yet been studied on a genome-wide scale in Cryptococcus.
Corresponding yeast homologs were identified for each of the
differentially expressed proteins listed in Table S2 (Table S3).
Seventy-seven of the 82 cryptococcal proteins had a yeast homolog
with an E value of less than 1029. Of these, 47 were present in the
yeast protein-protein interaction datasets used, which only include
interactions that have been experimentally validated [11,12].
Using these 47 yeast proteins, two different types of networks were
built to investigate the overall cellular drug response in C. gattii.
These were seeded with the 47 homologs and extended to show
the most direct connections (shortest path) between these
homologs using known protein-protein interactions. Figure 4
depicts expression networks for the three time points (3, 4 and 6 h)
and shows how the expression of proteins differentially regulated
by FLC treatment changes over time (see Figure S1 for larger
version of these networks). Figure 5 shows the same network with
Gene Ontology (GO) data mapped to the differentially expressed
proteins (large spheres), the interacting proteins (small spheres) and
the interactions (lines) that join them.
A total of 182 yeast proteins, including the 47 homologs of the
differentially expressed C. gattii proteins, and 392 interactions,
were present in the networks. Among the differentially expressed
C. gattii proteins mapped to the network, three warrant further
investigation as putative drug targets due to their significance in
yeast cells and their interactions with multiple partners (Figure 5;
also see Figure S2C): ATPase involved in ubiquitin-mediated
protein degradation (yeast homolog: CDC48); ATPase belonging
to heat shock protein 70 family (yeast homolog: SSC1); and core
Sm protein Sm D3 of the Sm ring complex required for the
biogenesis of the small nuclear ribonucleoproteins (yeast homolog:
SMD3). Ten interacting proteins (thirteen essential proteins in
total, including the three mentioned above) that were not directly
responsive to FLC but are known to be essential in yeast were also
identified (Figure S2C): karyopherin a homolog (SRP1); two
karyopherin b subunits (PSE1 and KAP95); the catalytic subunit of
the main cell cycle-dependent kinase (CDC28); ubiquitin-like
protein (SMT3); and five subunits of the nuclear pore complex
(NUP1, NUP49, NUP57, NUP116, and NUP145).
Proteins with the same colour, indicating that they shared GO
term and assigned function, tended to cluster together. For
example, seven ATP synthesis proteins, including six that were
differentially expressed (ATP1-5 and ATP7) and one interacting
protein (ATP6), formed a tightly interacting group (Figure S2B;
circled in red). All of these proteins belong to components of
mitochondrial F1F0-ATP synthase, which is responsible for
producing ATP required to power and sustain virtually all cellular
processes in an organism. A group of proteins belonging to the
nuclear pore complex, including the five essential proteins
mentioned above, were highly interacting with each other (Figure
S2C; circled in black). Similarly, coordinated changes in expres-
sion are seen between proteins that share similar activities
(Figures 4 and 5). URA2 (bifunctional carbamoylphosphate
synthetase-aspartate transcarbamylase) and its connecting partner
CPA2 (large subunit of carbamoyl phosphate synthetase) both
share carbamoyl phosphate synthase activity, and the change in
STI1 (heat shock protein 90 co-chaperone) appears linked to
changes in the expression of its interaction partners SSA1 and
HSP104 (both heat shock proteins), such that these were both
consistently co-expressed.
Discussion
Antimicrobial treatment results in changes in both target and
non-target cellular processes, with the latter generally evoked in
response to slowed growth and stress as the cell attempts to cope
with the damage induced by the antibiotic. The aim of this work
was to analyze the overall cellular response in the soluble
proteome of a typically sensitive C. gattii cell. Network analysis
identified a number of key hub proteins in this response that
govern a number of interacting cellular pathways; these warrant
further investigation as putative targets to use synergistically with
FLC.
The time-course study of differentially expressed proteins (Table
S2), together with the network analysis (Figure 4), show clearly that
C. gattii cells respond to FLC in a dynamic manner that operates in
an integrated fashion, and that although replication and growth
are impaired by FLC, many proteins are up-regulated, even after
6 hours of treatment. Particularly interesting in this regard is the
clustering and coordinated regulation over time of proteins ATP1-
7, which are components of mitochondrial F1F0-ATP synthase
(Figures 4 and 5; also see Figure S2B). ATP synthase consists of a
membrane-bound F0 component and a water soluble F1
component [13]. ATP1 and ATP2 (the a and b subunits) belong
to the F1 component with ATP3 (c subunit) forming the central
stalk. ATP4-7 are part of the F0 complex, while ATP6 is a key
component of the proton channel [14,15]. In this study, induced
expression of ATP5, which is essential for binding F1 and F0 and
forming an active complex, was up-regulated at 3 and 4 hours,
followed by up-regulation of ATP3 at 4 hours, then up-regulation
of the core subunits ATP1 and ATP2 at 6 hours. This indicates a
coordinated initiation of ATP synthase in response to FLC, which
may be required to drive ATP-dependent efflux pumps. This
observation of the systematic regulation of components of ATPase
complex over time is consistent with their structure and biological
function, and as well as aiding our understanding of the cellular
response to FLC is a useful validation of the proteome data.
In addition to the ATP synthase complex and several
mitochondrial respiratory proteins (cytochrome c oxidase subunit
2, inorganic phosphate transporter, NADH dehydrogenase and
ubiquinol-cytochrome C reductase complex core protein 2), FLC
treatment induced a number of other proteins involved in energy
metabolism. Enzymes involved in the gluconeogenesis pathway,
where pyruvate is converted back to glucose for energy
production, were increasingly up-regulated over the experimental
time-course, including enolase, fructose-bisphosphate aldolase,
glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate
kinase (Table S3). This suggests that a high level of energy was
required for survival in response to FLC. One possible survival
mechanism is to use an efflux system to remove toxic sterol
intermediates or foreign compounds such as FLC. The efflux
system is a survival and regulatory mechanism in yeasts that has
been found to contribute to antifungal drug resistance [16,17], and
is an energy-dependent system driven by ATP. Nutrient stress
during infection is likely to limit the ability of C. gattii cells to obtain
all their energy needs, and this may aid in the ability of FLC,
which is a fungistatic drug, to effectively contain and kill fungal
cells.
FLC induced a number of proteins involved in glycolysis and
carbohydrate metabolism, however proteins involved in the TCA
cycle were not detected (Table S1), indicating that normal
carbohydrate metabolism was no longer being achieved. This
suggests that alternative pathways have been employed to use the
products of the glycolytic pathway for growth and survival. The
trehalose cycle is a pathway branched from glycolysis that yeast
cells use to produce trehalose, a crucial protector of proteins and
membranes against osmotic, heat shock and oxidative stress,
starvation and toxicants [18,19], and phosphoglucomutase catal-
yses the first reaction in this cycle. This enzyme was induced at the
Cryptococcus Proteome in Response to Fluconazole
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6-h time point, suggesting that the trehalose cycle had been
initiated to protect cells from FLC. This is further supported by an
increased expression of UDP-glucose dehydrogenase, which
produces UDP-glucose required for the trehalose cycle. Pyruvate
kinase converts phosphoenolpyruvate to pyruvate, which is then
catalyzed to produce acetyl-CoA in the glycolytic pathway. Acetyl-
CoA can then enter the TCA cycle to generate ATP or can be
used via the fatty acid biosynthesis pathway to produce sterols and
lipids that are required for rigidity and integrity of the cell
membrane [20,21]. The induction of pyruvate kinase, fatty acid
synthase complex protein and isoprenoid biosynthesis-related
protein for sterol synthesis during growth in the presence of
FLC suggests that the fatty acid biosynthesis pathway was the
preferred pathway followed by glycolysis, and that cells might have
been restoring membrane defects caused by FLC via this pathway.
This is consistent with findings in C. neoformans [22] where
transcriptional analysis suggested that fungal cells use lipid
biosynthesis and metabolism to counterbalance ergosterol alter-
ation in response to FLC.
Not surprisingly, FLC treatment induced the expression of a
number of stress-related proteins. FLC is known to target
ergosterol biosynthesis by inhibiting the activity of lanosterol
demethylase [23], resulting in an increase in the accumulation of
toxic intermediate lanosterol. In addition to toxic stress, FLC is
likely to have induced membrane stress as cells grew larger but
failed to divide (Figure 2). When the growth of plasma membrane
is inhibited by FLC, continued synthesis of new proteins will
eventually stretch the cells, leading to a stress response at the
membrane. In this study, proteins found to function in protein
synthesis (ATP-dependent RNA helicase Eif4a, elongation factor
1-gamma, eukaryotic translation initiation factor 5C homolog,
MMS2, peptidyl-prolyl cis-trans isomerase D, translation elonga-
tion factor 2, and ubiquitin activating enzyme) were increasingly
expressed during FLC treatment over time (Tables S2 and S3),
indicating that new proteins were being synthesized. The present
study also revealed that cells treated with FLC for over 4 h were
significantly larger than those without FLC treatment (Figure 2).
These findings suggest that the properties and functions of the cell
wall and membrane were altered by the drug, as expected by its
mechanism of action, resulting in the failure of proper cell growth
and division. Previous studies of the effect of azoles on the
morphology of C. neoformans have reported similar changes [24,25].
The increase in protein synthesis, accompanied by impairment of
cell division leading to enlarged cells, is likely to stress the cell
membrane and cause an increase in various stress response
proteins. FLC is also known to cause oxidative damage [10], and a
consistent up-regulation of thiol-specific antioxidant protein 1
supports this view. These results are consistent with transcriptional
profiling of C. neoformans in response to FLC, where an up-
regulation of genes encoding proteins involved in the oxidative
Figure 4. Drug response network analysis based on the change
in protein expression over time. Spheres represent proteins and
lines connecting spheres indicate interactions between proteins. Large
spheres are proteins differentially expressed in response to FLC; red
indicates proteins induced or up-regulated; green indicates proteins
suppressed or down-regulated; and blue indicates no data at that time
point. Smaller spheres are colour-mapped according to Gene Ontology
biological process. The network analysis reveals correlated processes in
response to FLC treatment from 3 h to 6 h time points. See Figure 5 for
the Gene Ontology terms of these proteins. [GEOMI Force Directed
Layout: spring= 50, origin = 80, repulsion= 12, planar = 100].
doi:10.1371/journal.pone.0042835.g004
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stress response including thiol-specific antioxidant protein 3 was
also seen [22].
Although protein synthesis continued, the production of the
majority of ribosomal proteins was down-regulated in response to
FLC (Table S2), consistent with reduced protein yield for samples
treated with FLC for 4 and 6 h, and with other studies of fungi
treated with antifungal agents such as amphotericin B and FLC
[26,27]. However, two ribosomal proteins were consistently up-
regulated: 40S ribosomal protein S7 and 60S ribosomal protein
L6. 40S ribosomal protein S7 is crucial for cell viability in S.
cerevisiae [28], and the 60S ribosomal protein L6 is an N-terminally
acetylated protein component of the large ribosomal subunit. It is
difficult to explain why certain ribosomal components would be
up-regulated while overall the ribosomes are down-regulated, but
this may point to functions that are independent of their roles in
the ribosomes. Their consistent up-regulation suggests they might
play an important role in the response to FLC and may help C.
gattii maintain growth and survival.
Two proteins specific to fungal processes were differentially
expressed during FLC treatment (Table S2). The first, G-protein
beta subunit Gib2, was consistently down-regulated in response to
FLC over time. This protein functions in a G-protein signaling
system [29] and is essential for survival and viability in C.
neoformans. However, although it is a Gb-like/RACK1 protein
homolog, Gib2 is an atypical protein that appears to be specific to
Cryptococcus, which may limit its use as a broad-spectrum antifungal
target. The second protein, isoprenoid biosynthesis-related pro-
tein, was not detected at 3 hours but became up-regulated at the
later stage of the drug response. This protein is similar to yeast
farnesyl pyrophosphate (FPP) synthetase, and is involved in sterol
biosynthesis by producing isoprenes that are required at the early
steps of ergosterol synthesis [30].
Two other proteins found consistently up-regulated during FLC
treatment over time were 14-3-3 protein and peripheral-type
benzodiazepine receptor (Table S2). 14-3-3 protein is highly
conserved among the fungi and is involved in signal transduction,
controlling many cellular processes such as pseudohyphal induc-
tion, bud cell development and virulence-associated morphogen-
esis [31,32]. In S. cerevisiae, mutations in the 14-3-3 protein have
been shown to confer resistance to rapamycin, an immunosup-
pressant drug [33]. In Cryptococcus, 14-3-3 protein is immunodo-
minant in koalas with a subclinical Cryptococcus infection and in
mice with pulmonary disease, and is up-regulated in rabbits with
cryptococcal meningitis [34,35]. These findings, and the consistent
Figure 5. Drug response network drawn as in Figure 4 and coloured using Gene Ontology data. Network analysis reveals clustering of
protein with similar functions and hub proteins with a high degree of connectivity. Potential targets for synergistic therapies are indicated in Figure
S2. [GEOMI Force Directed Layout: spring= 50, origin = 80, repulsion= 12, planar = 100].
doi:10.1371/journal.pone.0042835.g005
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response of the 14-3-3 protein to FLC, indicate that it may play an
important role in cell survival in the presence of drug and in the
infected host. Peripheral-type benzodiazepine receptor, also
known as translocator protein, is localized primarily on the outer
mitochondrial membrane. It interacts with and utilizes porphyrins
as endogenous ligands [36], and functions in the regulation of
cholesterol transport for steroid biosynthesis in mammalian cells
[37]. This protein is essential for stress adaptation in plants [38],
thus the consistent up-regulation of this protein in C. gattii cells
exposed to FLC may also be a stress response.
Not all proteins known to be involved in drug responses were
detected in this analysis, and some of the most notable absences
included lanosterol 14a-demethylase, and membrane transport
proteins, such as ABC transporters and major facilitator super-
family transporters. Consistent with this, these proteins were not
identified in a similar study that examined the soluble protein
expression of C. albicans in response to ketoconazole [10].
However, expression of genes encoding these proteins has been
seen in transcriptomic studies in C. neoformans, S. cerevisiae and C.
albicans [22,39,40]. This indicates the limitations of gel-based
proteomics, where membrane-bound and low abundance proteins
are difficult to detect [41,42] and argues for the use of
complementary transcriptome and proteomic analyses, where
possible.
The integrative network analysis identified a number of hub
proteins that had multiple interaction partners and are likely to be
essential for cell survival [43,44,45]. A number of other essential
proteins were found based on information in Saccharomyces Genome
Database and other published studies (Figure S2C; black arrows).
These essential proteins are not fungal specific and play important
roles in mammalian cells, and therefore cannot be the direct target
of antifungal drugs. However, studies of drug synergy find the
amount of drug needed to completely inhibit the growth of fungal
cells can be reduced by more than 30-fold when used in
combination [46,47,48], and these may be useful targets for
combination therapies. As an example of this, inhibitors of
calcineurin, which is important in both fungi and mammals, have
been proposed for use in combination with FLC as in very small
amounts these convert FLC from being fungistatic to being
potently fungicidal [46].
Three of the thirteen essential proteins were differentially
expressed in response to FLC. CDC48, which was highly up-
regulated at 6 hours, is an ATPase involved in ubiquitin-mediated
protein degradation, with an important role for maintaining the
cell wall integrity during heat stress [49]. Depletion of CDC48 can
trigger apoptosis [50], and cells are sensitive to oxidative stress
[51]. SSC1, which was consistently down-regulated, is an ATPase
belonging to heat shock protein 70 family that is a component of
mitochondrial inner membrane [52]. This protein has a role in
protein folding and translocation by using energy derived from
ATP hydrolysis [53,54]. Cells lacking functional SSC1 are not
viable [55], and reduction of SSC1 function causes aggregation of
mitochondria [56] and reduced fitness [57]. Finally, SMD3, which
went from being up-regulated at 3 and 4 hours to down-regulated
at 6 hours, belongs to the highly conserved Sm protein family and
is associated with the biogenesis of the small nuclear ribonucleo-
proteins that function in post-translational modification of RNA
[58,59]. Cells with reduced expression of SMD3 show decreased
levels of small nuclear ribonucleoproteins [58], leading to
incomplete RNA processing. The other ten essential proteins
found in the network include SRP1, PSE1, KAP95, CDC28,
SMT3, NUP1, NUP49, NUP57, NUP116, and NUP145. SRP1,
PSE1 and KAP95 are a group of karyopherins that interact with
the nuclear pore complex and play a role in the transport of
nuclear proteins and the regulation of protein degradation and
desumoylation [60,61,62]. Disruption of these results in major
defects in cell morphology and growth [61,62,63]. CDC28 is a
catalytic subunit of the main cell cycle-dependent kinase that
regulates cell growth by controlling the timing of mitotic
commitment, bud initiation, DNA replication, spindle formation,
and chromosome separation [64]; mutations result in defects in
actin polarization and distribution with a failure to bud [65].
SMT3, a ubiquitin-like protein that regulates chromatid cohesion,
chromosome segregation, proteolysis, DNA replication and septin
ring dynamics [66,67,68], when mutated results in improper
chromosome segregation [68], leading to a larger cell size as
observed in this study. Finally, NUP1, NUP49, NUP57, NUP116,
and NUP145 are a group of essential proteins belonging to the
nuclear pore complex that interacts with SRP1, PSE1 and KAP95.
Mutations in genes encoding these proteins cause defects in
nuclear protein import, nuclear RNA export, nuclear pore
complex assembly, and nuclear envelope integrity [69,70,71]. As
all these essential proteins are involved in the overall control of a
range of important cellular functions required to maintain the
fitness of an organism, and although not fungal-specific, they may
be useful starting points for identifying novel drug targets. Our
future studies will assess whether depleting these proteins
significantly affects the response of C. gattii and other fungi to FLC.
Conclusion
This study examined the effect of FLC on the growth dynamics
and the proteome of C. gattii using a label-free quantitative
proteomic approach, and provided a broad overview of the
response in this fungus to FLC. The analysis revealed numerous
cellular proteins affected during growth and in response to FLC,
and showed the dynamic changes in the expression of these
proteins over time. The expression of proteins involved in
macromolecule biosynthesis and energy production for growth
was disrupted in the FLC-treated samples, and the abundance of
proteins responsible for the stress response, energy production and
macromolecule biosynthesis was altered throughout the three
stages of drug exposure. An integrative network analysis revealed
coordinated processes involved in the drug response and
highlighted potential drug targets that may be suitable for
synergistic therapies with FLC. Further studies are required to
test if these can enhance antifungal activity and limit the
development of drug resistance.
Materials and Methods
Strains and growth conditions
Cryptococcus gattii VGII strain V5, previously found to be
moderately susceptible to FLC (MIC=8 mg/mL) [7], was assessed
for growth in the presence and absence of FLC (Sigma-Aldrich,
Castle Hill, New South Wales) [7]. To establish growth curves,
individual colonies were picked from one-day old agar plates and
suspended in 25 mL of YPD broth (1% yeast extract, 2% peptone
and 2% dextrose). Cultures were grown in a Ratek Orbital Mixer
Incubator (Ratek Instruments Pty. Ltd., Victoria, Australia) at
37uC, 200 rpm to mid-logarithmic phase. When a cell density of
approximately 86105 viable cells/mL was obtained, FLC was
added to give a final concentration of 0, 20 and 100 mg/mL.
Cultures were grown at 37uC, 200 rpm, and aliquots were
removed at the indicated time points to assess cell numbers using
a haemocytometer, and cell viability, which was determined by
trypan blue staining (Sigma-Aldrich, Castle Hill, New South
Wales). Three replicates were measured for each sample at each
time point and averaged.
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Based on the initial growth curves, 20 mg/mL of FLC was
chosen as the most suitable concentration for proteome analysis.
To ensure that any changes to the proteome were most likely to be
a result of drug exposure, and not due to secondary effects (ie.
nutrient starvation or cell death), V5 cells were initially harvested
for protein extraction at 3 h, when they were beginning to respond
to the presence of FLC but there was only a small difference in
growth of the treated and untreated cells. Subsequent time points
of 4 and 6 h were selected, with the 4 h time point showing growth
in the presence of FLC had started to slow; and 6 h where a clear
difference between the treated and untreated cultures was seen.
Cell imaging
Aliquots of V5 cultures removed at 3, 4 and 6 h were visualised
using a Leica DME microscope (Leica Microsystems, Wetzlar,
Germany) equipped with an OMCAM30 3.0 megapixel USB
eyepiece camera (Aunet Scientific Products, Perth, WA). Cells
were stained with trypan blue to assess viability and counter-
strained with India ink to assess cell and capsule size. Cell size was
determined with ImageJ 1.44p by measuring the diameter of the
cell, and capsule size was measured by subtracting the cell size
from the diameter of the cell and capsule. Cell volume was
calculated based on the average cell radius, using the formula 4/
3pr3. PASW Statistics 17 (SPSS Inc., version 17) was used to detect
differences in cell and capsule sizes by the Independent-Sample t-
test.
Protein extraction
C. gattii strain V5 was grown in 25 mL of YPD broth at 37uC,
200 rpm to mid-log phase (,86105 viable cells/mL) and treated
with FLC at a concentration of 20 mg/mL. Cells were harvested at
3, 4 and 6 h post treatment by centrifugation at 4,000 g for
10 minutes at 4uC, and washed twice in 20 mL of ice-cold distilled
water supplemented with 0.56protease inhibitors (Roche Applied
Science, Sydney, NSW, Australia). The cell pellets were
resuspended in extraction buffer (7 M urea, 2 M thiourea, 1%
C7bzO, 40 mM Tris and 50 mM lithium chloride) supplemented
with 16 protease inhibitors, to a concentration of 0.3 mL wet
volume of cells/mL buffer, and were disrupted using 2.0 mm glass
beads and a Mikro Dismembrator II (B. Braun Biotech, Allen-
town, PA) at full speed for 5 minutes. Cell lysates were treated with
a final concentration of 10 mM tributylphosphine (Sigma-Aldrich,
Castle Hill, New South Wales) and acrylamide (Bio-Rad
Laboratories, Inc, Hercules, CA, USA) to reduce and alkylate
disulfide bonds simultaneously, followed by sonication with a
Misonix Sonicator 3000 ultrasonic probe (Misonix, NY, USA) for
1 minute at full power, and cell breakage was checked under the
microscope to ensure complete cell lysis. Samples were cooled on
ice for 30 seconds and incubated at room temperature for
60 minutes. Following incubation, the cell-free supernatants were
collected by centrifugation at 16,000 g for 10 minutes and
transferred to acetone (Sigma, St Louise, MO, USA) for protein
precipitation at room temperature for 60 minutes. Precipitated
proteins were collected by centrifugation at 3,000 g for 10 minutes
and suspended in SDS sample buffer (2% SDS, 40 mM Tris-HCl,
pH 6.8, 10% glycerol and 0.1% bromophenol blue). Protein
concentration was determined using bovine serum albumin
standards in a gel-based assay, and the samples were heated at
90uC for 5 minutes prior to one-dimensional gel electrophoresis.
PASW Statistics 17 was used to detect differences in protein yields
among samples by the Paired-Sample t-test. Three biological and
three technical replicates were conducted for each sample to
ensure reproducibility. Since the technical replicates from the 3 h
samples had a high level of reproducibility, and multiple time
points were selected for the study, only the three biological
replicates were analyzed for the 4 and 6 h samples.
One-dimensional (1D) gel electrophoresis
Approximately 120 mg of extracted protein was loaded onto a
12-well Criterion XT precast polyacrylamide gel with 4–12% Bis-
Tris (Bio-Rad, Hercules, CA, USA), alongside a Precision Plus
Protein unstained standard molecular weight marker (Bio-Rad,
Hercules, CA, USA). The protein samples were separated by
electrophoresis in MES running buffer at 160 V until the dye front
ran off the gels. Gels were then fixed in a solution containing 40%
methanol and 10% acetic acid for 30 minutes, stained overnight
with Flamingo quantitative fluorescent gel stain (Bio-Rad Labo-
ratories, Inc, Hercules, CA, USA) and imaged at medium intensity
with 50 mm pixel size resolution using a Bio-Rad Pharos FX Plus
molecular imager (Bio-Rad Laboratories, Inc, Hercules, CA,
USA). Lanes containing separated proteins were excised from the
stained gels and sliced evenly into twenty fractions. Each fraction
was finely macerated, and gel pieces from each fraction were
subjected to trypsin in-gel digestion for mass spectrometry as
described previously [34].
Protein identification and validation
Mass spectra for each sample fraction were recorded on a
QSTAR Elite hybrid quadrupole-time-of-flight mass spectrometer
(Applied Biosystems/MDS Sciex, Carlsbad, CA, USA), and MS/
MS data generated for the twenty fractions were merged using
Mascot Daemon (Matrix Science, London, England, Thermo).
Data were then searched against the LudwigNR databases (ftp://
ftp.ch.embnet.org/pub/databases/nr_prot) to identify proteins
using the Mascot algorithm (version 2.1.0) provided by the
Australian Proteomics Computational Facility (http://www.apcf.
edu.au/). The search parameters were as follows: propionamide
modifications with possible oxidation of methionine, trypsin digest
with three missing cleavages, peptide mass tolerance of
6100 ppm, and MS/MS mass tolerance of60.2 Da. A significant
probability-based Mowse score (p,0.05) was used as the criterion
for correct protein identification. Searches against a decoy
database were performed to validate searches of MS/MS data.
MS/MS data and protein identifications assessed by Mascot
were further validated and analysed using Scaffold (version
2.01.02, Proteome Software Inc., Portland). Protein identifications
that had .95% protein probability with at least two unique
peptides, as specified by the Protein Prophet algorithm [72], and
.95% peptide probability, based on the Peptide Prophet
algorithm [73], were accepted. Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
Proteins that were identified in all three biological samples were
included for the analysis. Among all the identified proteins, several
did not appear to belong to Cryptococcus species. However,
sequence alignment of these non-cryptococcal proteins with the
closely related cryptococcal proteins revealed a high sequence
similarity (data not shown). As these proteins met all the filter
criteria and were found in all three biological samples, they were
included in the analysis. Biological functions of the identified
proteins were obtained from the ExPASy Proteomics Server
(http://ca.expasy.org/) based on Cryptococcus species or other
fungal pathogens. Spectral count results of the identified proteins
were normalised to reduce technical bias and produce high quality
counts for quantitative analysis [74]. Differentially expressed
proteins determined from normalised spectrum counts showing an
at least 2-fold change in abundance in at least two of the three
biological samples were analysed to detect differences in
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abundance by the t-Test provided in Scaffold. The Levene Statistic
was used to assess differences in homogeneity between samples.
Protein interaction networks using GEOMI
Proteins that were differentially regulated in response to FLC
were further examined to study protein-protein interactions.
GEOmetry for Maximum Insight (GEOMI; http://www.
systemsbiology.org.au/downloads_geomi.html) [75] was used to
visualize cellular interaction networks using two high-quality yeast
protein-protein interaction metadatasets collated by Bertin et al.
[12] and Yu et al. [11]. To generate the networks, yeast homologs
of cryptococcal proteins that were differentially expressed over the
three time points (Table S2) were first identified using the Clusters
of Orthologous Groups (http://www.ncbi.nlm.nih.gov/COG/)
[76] or the Saccharomyces Genome Database (http://www.
yeastgenome.org/). A match with an E-value of less than 1029
was considered acceptable (Table S3). Due to the differences
between Cryptococcus and S. cerevisiae as well as current experimental
limitations of detecting protein-protein interactions, not all
cryptococcal proteins had a yeast homolog and not all the yeast
orthologs were covered in the yeast network.
To minimise visual complexity, networks were generated by
seeding with yeast homologs, and extending to show the most
direct connections (shortest path) with known protein-protein
interactions. Network layout algorithms such as Spring Force,
Repulsion Force, Origin Force and Planar Force parameters were
then optimised to filter out undesired details and enhance the
visualisation in 3D. Proteomic data were mapped onto the drug
response networks to contextualise and highlight different aspects
of the yeast homologs. This allowed the networks to be analysed in
two ways. One was based on the protein expression of
differentially regulated proteins in response to FLC, which allows
visualisation of the change in protein expression over time; the
other was based on Gene Ontology (GO) terms that identifies the
functions of the proteins in the interactome network, and can be
used to deduce the cellular context of the differentially expressed
proteins. The differentially expressed proteins were highlighted (by
larger size) to distinguish them from their interacting partners in
both networks, and a different color was assigned to each
biological process in the latter network, as annotated by the Gene
Ontology term.
Supporting Information
Figure S1 Larger version of drug response networks
shown in Figure 4.
(PDF)
Figure S2 Larger version of drug response networks
shown in Figure 5. Black arrows indicate essential proteins; red
arrows show proteins involved in coordinated process in drug
response (see Figure 4 for expression of these proteins).
(PDF)
Table S1 Cryptococcus gattii proteins differentially
expressed during growth with and without FLC.
(PDF)
Table S2 Differential expression of Cryptococcus gattii
proteins over time in response to FLC.
(PDF)
Table S3 Identification of yeast homologs for crypto-
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